Eight in 10 Pennsylvanians are at least slightly worried about affording their prescriptions, and 87% support the creation of a state regulatory body to help keep drug prices within reach, a new poll found. The results of the survey were presented Thursday during a webinar hosted by Rep. Dan Frankel, D-Allegheny, the sponsor of legislation establishing a Prescription Drug Affordability Board, along with health care advocates.
The poll was conducted by Embold Research and Families USA, both nonpartisan groups specializing in health equity, research and policy. Results from the June 15-21 survey of 1,596 registered Pennsylvania voters found that 68% of respondents saw prescription drugs as at least “somewhat unaffordable.” Worry was most acute for those with a household income below $50,000 and those between the ages of 50 and 64.
Spurred by steadily rising prescription drug costs, a number of states, starting with Maryland in 2019, have established Prescription Drug Affordability Boards. Just in July, New Jersey joined in, as Gov. Phil Murphy signed a bill to establish a PDAB with the hope of capping costs of expensive medication like insulin, EpiPens and inhalers. According to the Pennsylvania Health Access Network, 12 additional states are interested in creating their own regulatory boards.
At the federal level, the Biden Administration’s Inflation Reduction Act is expected to limit costs for expensive medications. In June, the U.S. Department of Health and Human Services announced actions to help Medicare lower health care costs by negotiating directly with drug companies.
“Prescription drugs play a critical role in managing health conditions, but prescription drugs don’t work if people can’t afford them,” said Antoinette Kraus during the Thursday webinar. Ms. Kraus is the executive director of PHAN, a nonprofit that provides health resources to consumers and advocates for health equity, and which co-hosted the video meeting.
The Pennsylvania Prescription Drug Affordability Board would be made up of legislators and experts and would aim to identify questionable drug management practices, review prescription drug costs and decide on a price cap for those drugs.
Sponsored by Rep. Frankel, House Bill 1722 — which would establish a state Drug Affordability Board — was introduced in January 2021. Mr. Frankel, who is chair of the House health committee, said he is in talks with Gov. Josh Shapiro to reintroduce the bill for the coming fall legislative session, which reconvenes on Sept. 26. He recognized the need for bipartisan support, considering the Senate currently has a Republican majority.
Rep. Kathy Rapp, R-Warren and the minority House health committee chair, said she has some concerns about the bill that will be discussed when the next legislative session begins. Specifically, she’s wary of the possibility that a state board would break interstate commerce laws, as drug supply chains are global.
She also wasn’t convinced that a board to cap drug prices would solve cost problems for consumers.
“We all want to see drugs be more affordable for our constituents. It’s just, how do we go about that in the right way?” she said during a Friday phone call.
She expected her Republican colleagues might broach similar concerns, but because the House is majority Democrat, she wasn’t sure that meant the bill would fail in the House.
Rep. Frankel, through an assistant, declined to comment in response.
Paul Schemel, R-Franklin, who asked questions about the bill in the April committee meeting, could not immediately be reached for comment. Eric Nelson, R-Westmoreland, was unable to respond by press time.
“We know people are worried about prescription drug costs,” said Mr. Frankel in the webinar. “We know far too much to do nothing.
“We need a balanced approach that fosters innovation for new medicines, but not at the expense of making those new medicines unavailable to people who need them,” Mr. Frankel said in an April health committee meeting about the creation of a board.
Such advisory boards already exist for similar services, such as electricity and water, he noted during the Thursday webinar. “These medications are just as important to survival as these other utilities. … This is legislation that would basically establish the equivalent of a public utility commission for prescription drugs.”
Survey respondents in support of the affordability board spanned gender, age and party, with 94% of Democrats and 75% of Republicans in support. Those behind the board’s creation also reside throughout the Commonwealth, with the highest percentage of support coming from the northwestern part of the state (92%).
Paula Work, a teacher and mother who lives in Sewickley, spoke during the meeting about her own experience being forced to choose between paying for lifesaving cancer drugs or her bills. Ms. Work was diagnosed with stage 4 ovarian cancer after visiting the emergency room with unresolved stomach pain. She said she underwent eight chemotherapy treatments and suffered from bone pain and neuropathy during this time.
During her treatment, she turned 65, and was transferred from private insurance to Medicare, she said. While her chemo drug, Zejula, was covered in full under her private plan, it was not covered under Medicare.
“I was approved for free prescription drugs at age 64, and not at age 65,” she said, her voice shaky. “Who is winning this battle — chemo or me?”
Hanna Webster: hwebster@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.